Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial

@article{Mesu2018OralFF,
  title={Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial},
  author={Victor Kande Betu Ku Mesu and Wilfried Mutombo Kalonji and Cl{\'e}lia Bardonneau and Olaf Valverde Mordt and Antoine Tarral},
  journal={The Lancet},
  year={2018},
  volume={391},
  pages={144-154}
}
  • Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, +2 authors Antoine Tarral
  • Published 2018
  • Medicine
  • The Lancet
  • BACKGROUND Few therapeutic options are available to treat the late-stage of human African trypanosomiasis, a neglected tropical disease, caused by Trypanosoma brucei gambiense (g-HAT). The firstline treatment is a combination therapy of oral nifurtimox and intravenous eflornithine that needs to be administered in a hospital setting by trained personnel, which is not optimal given that patients often live in remote areas with few health resources. Therefore, we aimed to assess the safety and… CONTINUE READING
    116 Citations
    Neopterin and CXCL-13 in Diagnosis and Follow-Up of Trypanosoma brucei gambiense Sleeping Sickness: Lessons from the Field in Angola
    • 1
    • PDF
    Trypanocidal treatment of Chagas disease.
    Human African Trypanosomiasis: Progress and Stagnation.
    • 11
    Fexinidazole: First Global Approval
    • 58
    • Highly Influenced

    References

    SHOWING 1-10 OF 21 REFERENCES
    Human African trypanosomiasis
    • 404
    • PDF
    Epidemiology of human African trypanosomiasis
    • 279
    • PDF
    Human African trypanosomiasis in the Democratic Republic of the Congo: disease distribution and risk
    • 38